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ABSTRACT
Background: Safety data of the ‘real life’ use of an infliximab biosimilar, CT-P13 in inflammatory bowel
disease (IBD) are still lacking. Our aim was to assess the frequency and characteristics of infusion
reactions during CT-P13 therapy in 13 Hungarian and 1 Czech IBD centres.
Methods: Clinical and safety data was registered at fixed appointments. Trough levels and anti-drug
antibody (ADA) concentration were measured by ELISA. Association between demographic, clinical,
laboratory parameters and infusion reaction rates were evaluated statistically.
Results: Three hundred and eighty-four IBD patients were included. Twenty-eight Hungarian IBD
patients (9.6%) developed infusion reaction during the treatment, 64.3% of them was previously
exposed to anti TNF therapy. No infusion reaction occurred in the Czech population. CT-P13 therapy
had to be stopped in 17 patients who developed infusion reaction and was switched to adalimumab in
12 patients. However in 39.3% of patients developing infusion reaction CT-P13 therapy was continued
with the use of premedication. Cumulative ADA positivity rates were 8.7%, 19.3%, and 28.0% at weeks 0,
14, and 30. Previous anti-TNF-alpha exposure (30% vs. 3.1%, p < 0.001, OR 6.3 (2.7–14.6)) and ADA
positivity (32.6% vs. 4.1%, p < 0.001, OR 19(5–73)) during the induction therapy were predictive factors
for infusion reactions.
Conclusions: Patients with previous exposure to anti-TNF-alpha and ADA positivity during the induction
therapy were more likely to develop infusion reactions.
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1. Introduction
After some case series, a large, prospective Hungarian multicenter
study has confirmed the efficacy of CT-P13, the first infliximab
biosimilar, in inducing and maintaining remission in both Crohn’s
disease (CD) and ulcerative colitis (UC) [1–5]. However, besides
efficacy data, safety assessment is also very important when extra-
polating indications for biosimilars. Immunological reactions
including immunogenicity and infusion-related reactions are one
of the main limiting factors of the originator infliximab (IFX), a
chimeric mouse-human monoclonal antibody to TNF-alpha, and
one of the most important concerns before the start of using
biosimilar IFX. Immediate infusion reactions, developing during
the course of the infusion or within 1–2 h of its completion, are
reported in 5–23% of IBD patients receiving originator IFX [6].
Patients who develop antibodies to IFX have been shown to
have a 2-fold risk of acute infusion reactions and a 6-fold risk of
serious acute infusion reactions [7]. In the two pivotal trials,
Programme evaLuating the Autoimmune disease iNvEstigational
drug cT-p13 in rheumatoid arthritis (RA) patients (PLANETRA) and
Programme evaLuating the Autoimmune disease iNvEstigational
drug cT-p13 in ankylosing spondylitis (AS) patients (PLANETAS),
comparing CT-P13 with the reference IFX in patients with
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rheumatoid arthritis and ankylosing spondylitis, rates of infusion
reactions were 6.6% and 8.3% of rheumatoid arthritis patients and
3.9% and 4.9% of patients with ankylosing spondylitis for the IFX
biosimilar, CT-P13 and for the originator IFX [8,9]. Despite these
conclusive safety data, immunogenicity of monoclonal antibodies
is a major safety concern for the biosimilars. The study published
by Ben-Horin et al. in 2015 examined the presence of cross-immu-
nogenicity of IFX biosimilar CT-P13 with the originator drug. Their
findings indicated that antibodies to originator IFX developed
during the previous exposure to the drug were also cross-reactive
with the biosimilar IFX [10]. These data suggest a similar immuno-
genicity and shared immunodominant epitopes on these two IFX
agents.
According to the current central regulation, in Hungary, IFX
biosimilar has to be used in every new patient and is allowed
to be introduced in patients who previously responded to the
reference drug and at least one year elapsed after stopping
the originator IFX. Therefore, data on frequency and predictors
of infusion reactions developed during the administration of
CT-P13 from the clinical practice would be very important
when assessing the start of IFX biosimilar. This study aimed
to assess the frequency, characteristics and predictors of infu-
sion reactions during CT-P13 therapy.
2. Patients and methods
2.1. Patient population
This was a prospective, observational, multicenter study carried
out in 13 Hungarian and 1 Czech IBD tertiary centers between
June 2014 and September 2015. Consecutive IBD patients treated
with CT-P13 IFX biosimilar were prospectively enrolled in the study
(Inflectra®, Hospira was used in Hungary, Remsima®, Celltrion was
used in the Czech Republic). Eligible patients were older than
18 years and were diagnosed with CD or UC defined by the
European Crohn’s and Colitis Organisation (ECCO) Consensus
Report [11,12]. None of the enrolled patients received originator
IFXwithin 12months before initiation of CT-P13. Clinical datawere
collected according to a predefined monitoring strategy. CT-P13
5 mg/kg was given as an intravenous infusion at 0, 2, and 6 weeks
followed by a maintenance regimen of 5 mg/kg every 8 weeks
except for one Czech patient receiving 10 mg/kg induction dose
for acute, severe disease. Demographic data including history of
previous anti-TNF-alpha administration and concomitant medica-
tions were collected. Clinical data were recorded, disease activity
was evaluated by activity scores and blood sampleswere collected
for the measurement of serum inflammatory parameters (namely,
C-reactive protein, leukocyte, hematocrit, thrombocyte, albumin),
CT-P13 and anti-drug antibody (ADA) levels during the visits.
Clinical response was estimated at fixed appointments through-
out the treatment period: at week 2, 4, 6, 14 and then at every
8 weeks.
CT-P13 trough levels and presence of ADA were assessed
by ELISA (LISA TRACKER, Theradiag, France in Hungary and
SHIKARI Q-Inflixi, Q-ATI, Matriks Biotek, Turkey in the Czech
Republic) at baseline, at weeks 14, 30, and 54 right before anti-
TNF administration.
The detection cut-off value of CT-P13 trough level was 0.1
μg/ml, while 3–7 μg/ml was defined as therapeutic. The
standard cut-off value of ADA level was 10 ng/ml. ADA posi-
tivity was defined above the cut-off value of ADA level. ADA
formation was defined as positive when a patient tested posi-
tive for antibody during follow-up on more than two conse-
cutive time points. Association between infusion reactions,
demographic and clinical characteristics of patients such as
age, gender, smoking habits, type of IBD, extent of disease,
perianal involvement, disease activity, previous anti-TNF-alpha,
previous and concomitant azathioprine/5-aminosalicylates (5-
ASA)/corticosteroid use, and ADA positivity were statistically
analyzed. Therapy (reduction of the infusion rate, or adminis-
tration of iv. antihistamine and/or iv. steroid) and outcomes of
infusion reactions were prospectively evaluated.
2.2. Statistics
Datawere analyzedwith the use of SPSS 20.0 software. Descriptive
statistics were used to characterize patients’ demographics and
infusion reactions. ADA positivity rates were compared between
IFX-exposed and naive patients by Chi2 test or Fisher’s Exact test.
p < 0.05 was considered statistically significant.
3. Results
3.1. Patient population
Three hundred and eighty-four consecutive IBD patients (253
CD patients and 131 UC patients; 291 Hungarian, 93 Czech)
were included in the present cohort. Forty-five CD patients
and 15 UC patients had received previous anti-TNF-alpha
therapy in the Hungarian cohort, and none of the patients in
the Czech IBD population. 2.7% of CD and 4.6% of UC patients
received originator IFX and adalimumab treatment and 21.8%
of CD and 9.4% of UC patients received only originator IFX
prior CT-P13 therapy. Concomitant azathioprine therapy was
administered in 146 CD and 62 UC patients at inclusion
(Table 1). Mean CT-P13 trough levels were 20.1, 14.7, and
5 μg/ml at weeks 2, 6, and 14 (n = 124, 86 and 174). ADA
measurements were available in 229, 192, and 143 IBD
patients at baseline and at 14, 30 weeks. Cumulative ADA
positivity rates were 8.7%, 19.3%, and 28.0% in patients at
weeks 0, 14, and 30 (Figure 1).
3.2. Infusion reactions
Twenty-eight patients (9.6%, 18 CD, 10 UC) developed infusion
reaction during the induction and maintenance treatment.
Infusion reactions occurred most frequently during the 2nd
and 3rd infusion. The most common symptoms of infusion
reactions were flushing in 39.3%, dyspnea and chest pain in
25% and 14.3%, coughing in 17.8%, palpitation and tachycar-
dia in 10.7%, swelling of the throat in 10.7% and headache in
7.1%. All of the infusion reactions were mild to moderate. They
could be controlled by the reduction of the rate of infusion, or
administration of iv. antihistamine or iv. steroid. None of the
patients with infusion reaction required to be admitted to
intensive care unit. Clinical data of patients who developed
infusion reaction are summarized in Table 2. Notably, no sig-
nificant difference was observed in disease location and
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behavior between patient groups with and without develop-
ing infusion reactions.
In CD patients with infusion reaction, prior to biological
therapy with CT-P13 therapy, 15 patients received 5-ASA, 14
corticosteroid and 9 patients immunomodulator therapy ever
during the disease course. Thirteen CD patients with infusion
reaction received previous anti-TNF-alpha treatment; every
patient was treated with originator IFX. Regarding UC patients
who developed infusion reaction, prior to CT-P13 therapy 8
patients was treated with 5-ASA, 7 with corticosteroid and 5
with immunomodulator therapy during their whole disease
course. Five UC patients with infusion reaction were previously
treated anti-TNF-alpha drug; three of them with originator IFX,
and 2 patients with adalimumab. Overall, infusion reactions
occurred in 10 of 231 anti-TNF-alpha naive patients (4.3%).
ADA positivity was detected in 10 CD and 4 UC patients (8
CD and 3 UC patients were previously treated with anti-TNF-
alpha therapy) of 28 patients who developed infusion reaction
(Figure 2). Concomitant corticosteroid and azathioprine were
given for 7 and 9 CD and for 3 and 5 UC patients developing
infusion reaction during the CT-P13 therapy, respectively.
Dose escalation of CT-P13 from 5 mg/bwkg to 10 mg /bwkg
was necessary in two patients (one CD, one UC) with infusion
reaction during maintenance therapy.
CT-P13 therapy had to be stopped in 17 patients and was
switched to adalimumab in 12 patients. However, in 11 (39.3%)
patients, CT-P13 therapy was continued with the use of premedi-
cation (reduction of the rate of infusion, or administration of iv.
antihistamine or iv. steroid). Four patients who continued CT-P13
therapy with the use of premedication presented ADA positivity.
Infusion reactions did not occur in the Czech population;
moreover rate of infusion reaction was significantly higher in
anti-TNF-α naïve Hungarian patient than in anti-TNF-α naïve
Czech patients (p = 0.032). Previous anti-TNF-alpha exposure
(30% vs. 3.1%, p < 0.001, OR 6.3 (2.7–14.6)) and ADA positivity
(32.6% vs. 4.1%, p < 0.001, OR 19 [5–73]) during the induction
therapy were predictive to the development of infusion reac-
tions (Figures 3 and 4). No association was shown between
infusion reaction and gender, smoking status, type of disease,
extent/location, perianal involvement, disease activity, conco-
mitant or previous 5-ASA/steroids, and azathioprine therapy.
4. Discussion
This multicenter, prospective study examined the rate, the char-
acteristics, and the predictors of infusion reactions developed in
CT-P13-treated Hungarian and Czech IBD patients. Infusion reac-
tions occurred in 7.3%of all the enrolledpatients. 35.7%of patients
developing infusion reaction were anti-TNF naive. Frequency rate
of infusion reactions proved to be 9.6%of theHungarian patients –
in 64.3%ofCDand35.7%ofUCpatients. Anti-CT-P13 antibodywas
proved in 32.6% of patients with infusion reaction and 4.1% of
subjects without any reaction during treatment. Infusion reactions
occurred most frequently during the 2nd and 3rd infusions. The
most common symptoms of infusion reactions included flushing,
dyspnea, and chest discomfort. CT-P13 therapy had to be stopped
in themajority of the patients after the development of an infusion
reaction and switch to adalimumab was carried out in 43% of
them. CT-P13 therapy was continued with the use of simple or
combined premedication including reduction of the infusion rate
or use of antihistamine or steroid in almost 40% of the patients.
Infusion reactions are one of the most common limiting
factors of IFX therapy. Several possible mechanisms may be in
Table 1. Demographic and clinical data of the Hungarian and Czech IBD patients enrolled in the study.
Hungarian cohort Czech cohort Total
CD UC CD UC CD UC
Patient number 184 107 69 24 253 131
Mean age at diagnosis (years) 23 28 28.3 29.8 25.5 28.9
Previous anti-TNF-alpha therapy (No.) 45 15 0 0 45 15
Concomitant azathioprine therapy (No.) 111 55 35 7 146 62
Ileal location (No.) 31 0 14 0 45 0
Colonic location (No.) 60 0 16 0 76 0
Ileocolonic location (No.) 90 0 28 0 118 0
Upper GI location (No.) 3 0 11 0 14 0
Stricturing/penetrating behavior (No.) 76 0 36 0 112 0
Perianal disease (No.) 64 0 21 0 85 0
Previous surgery (No.) 41 0 21 0 62 0
Proctitis (No.) 0 9 0 1 0 10
Left-sided UC (No.) 0 35 0 9 0 44
Extensive colitis (No.) 0 63 0 14 0 77
Patients with ADA positivity 21 19 3 0 24 19
Figure 1. Cumulative ADA positivity rates in enrolled patients (8.7%, 19.3% and
28%; n = 229, 192 and 143) at weeks 0, 14, and 30.
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the background of infusion reactions including cytokine
release (immune cell hyperactivation, direct apoptosis, com-
plement-mediated lysis, antibody-dependent cellular toxicity),
IgE-mediated hypersensitivity reactions to IFX, IgG ana-
phlyaxis, complement activation, or direct mast cell degranu-
lation [13–15]. The most frequent symptoms of infusion
reaction are pruritus, flushing, dyspnea, chest discomfort,
hypertension, myalgia, nausea, urticaria, headache, rash, and
dizziness [16]. Although there is no specific guideline for the
treatment of IFX-related infusion reactions, according to ther-
apeutic recommendations based on case reports and expert
opinions, temporary attenuation of the infusion rate or tem-
porary interruption of the infusion with the administration of
medications for symptom control are usually eligible.
Coadministration of immunomodulator or premedication
with steroids and/or antihistamines is the most common inter-
ventions in the prevention of infusion reactions [6]. However,
only a smaller proportion of patients may continue treatment
with these premedications – in our study, almost 40% of the
patients could maintain CT-P13 treatment with supplementary
intervention and premedication.
Frequency rate of infusion reactions in CD patients seems
to be different when comparing to the large randomized
clinical trials conducted in CD patients receiving the originator
IFX. The incidence of infusion reactions was 16% and 21% in
ACCENT I and II studies, respectively [17,18]. The lowest inci-
dence of infusion reactions occurred among patients receiving
both steroids and immunosuppressives (8%) [17]. In our
cohort, 9.8% of the CD patients developed infusion reaction,
which is lower than that of the ACCENT trials. In ACT 1 and 2
infusion reactions occurred in 9.9% and 11.6% of UC patients
receiving 5 mg of IFX [19]. These results are highly similar to
our data where infusion reactions occurred in 9.3% of the UC
patients. In ACT 1, 35.7% of patients with antibody positivity
against IFX developed infusion reaction at week 54 [19].
Although the increasing data about the efficacy of IFX biosi-
milar confirmed that CT-P13 may be considered equivalent to its
reference drug in IBD in practice, collection of immunogenicity
data and immunological reactions in clinical practice is impor-
tant to compare the safety profile of the biosimilar and the
reference product especially if we only consider the ‘Eprex
Table 2. Characteristics of patients developing infusion reaction.
CD with infusion
reaction (n = 18)
UC with infusion
reaction (n = 10)
Gender (male/female) 6/12 5/5
Mean age at diagnosis (years) 22 27
Mean disease duration (years) 7 5
Previous therapy
1. 5-ASA 15 8
2. Corticosteroid 14 7
3. Azathioprine 9 5
4. Anti-TNF-alpha 13 5
Concomitant therapy at the
time of infusion reaction
1. Corticosteroid 7 3
2. Azathioprine 9 5
3. ADA positivity 10 4
Mean value of ADA titer at
infusion reaction (ng/ml)
655 743
Number of infusions at infusion
reaction
4. 2nd infusion 11 6
5. 3rd infusion 4 3
6. 4th infusion 2 1
7. 5th infusion 1
Figure 2. Serum ADA level distribution in patients with infusion reaction at
weeks 0, 2, 6 and 14.
Figure 3. Proportion of patients developing infusion reaction regarding previous anti-TNF-alpha use.
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case,’ when after a change in the formulation of epoetin-alfa,
patients developed antibodies against both the administered
epoetin and the endogenous erythropoietin, resulting in severe
pure red cell aplasia [20]. However, no relevant differences were
noted in the immunogenicity profiles of CT-P13 and reference
IFX in the PLANETRA and PLATENAS studies from rheumatology
[8,9]. In the Korean study by Kang et al., no serious adverse
reaction occurred during CT-P13 therapy [3]. Yung et al. experi-
enced adverse events in 6 UC patients (11.8%) including allergic
(skin rash, scaling of palm) and infusion reaction in half of these
patients [2].
In the Norwegian prospective study, one CD and one UC
patients developed infusion reaction [1]. The UC patient with
infusion reaction occurring at the second infusion was shown
to have undetectable trough serum levels of CT-P13 and ADA
positivity at week six. This patient had previously been treated
with IFX in two periods [1]. None of these studies were pow-
ered enough to obtain predictive factors for infusion reactions.
Infusion reaction did not occur in the Czech population, using
Remsima. In September 2013, the EMA issued the marketing
authorization of a biosimilar of Remicade, CT-P13, to 2 appli-
cants, Celltrion Inc. (Incheon, South Korea) and Hospira Inc.
(Lake Forest, IL) under the trade names Remsima and Inflectra
[21,22]. However, Remsima and Inflectra can be considered as
one product since they are both manufactured by Celltrion.
Although considered to have no clinical impact, differences in
impurities and break down products of the biosimilars can
affect immunogenicity. According to the recent study by Gils
et al., monoclonal antibodies raised against the originator
product Remicade revealed a highly similar reactivity toward
the biosimilars Remsima and Inflectra and with similar KD
values for both antibodies toward the different infliximab
molecules [23]. In the present study, LISA TRACKER
(Theradiag, France) and Matriks Biotek (Turkey) were used to
measure IFX biosimilar trough level and ADA concentration.
However, according to a recent Czech study, SHIKARI Q-Inflixi
(Matriks Biotek, Turkey), LISATracker Duo Infliximab
(Theradiag, France), and RIDASCREEN IFX (R-Biopharm,
Germany) assays were in perfect agreement in qualitative
and quantitative results for the majority of the samples.
These observations suggested that substitution between the
assay methods evaluated in the study is possible [24].
Our results showed that previous anti-TNF-α exposure and
presence of antidrug antibody proved to predict the develop-
ment of infusion reaction. Contrary to the Hungarian cohort,
Czech population involved only anti-TNF-alpha naïve IBD
patients. Considering these data, the absence of previous
anti-TNF-alpha exposure and ADA positivity may be the rea-
son for the lack of infusion reaction in the Czech cohort.
However, this study has no power to assess differences regard-
ing to immunogenicity between Inflectra and Remsima.
In conclusion, this large, multicenter study was the first
that evaluated the immunogenicity profile of CT-P13 in IBD
in the clinical practice, characterized infusion reactions in
this population and revealed predictors for infusion reac-
tion. Our results suppose a lower immunogenicity of the
biosimilar in CD and similar rates and characteristics of
infusion reaction with the originator. These data should
be confirmed by other large studies with the consideration
of potential differences in the characteristics of the patient
population and the disease phenotype.
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Figure 4. Proportion of patients developing infusion reaction regarding anti CT-P13, an IFX biosimilar antibody.
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